AMLN (DIABETES DRUGS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: celeryroot.com who wrote (908)	10/22/1997 12:27:00 AM
From: D.Right	Read Replies (1) of 2173

Dear Celeryroot: I believe AMLN will have a great future but I don't think it will ever be acquired by JNJ. If pramlintide sells great after approval, AMLN's management won't say yes to any offer. On the other hand, if it doesn't sell very well, JNJ won't offer. As for the four trials, we should get the news of enrollment completion in the next couple weeks (my calculation, no insider informations whatsoever). Then it should take six months from there to complete the trails and two to three months more to analyse data. So, it should be around the July to Sept. time frame of next year. Actrally, the future of AMLN will be decided once the enrollment is done, everything will be automatic from there. I believe that is why the company is taking its time now. If you have read their news release from last two trial IIIs carefully, you will find that the question is not whether they will improve their number of HbA1c reduction but how much. The patients enrollment alone should have 33% improvement for type I and about 20% in type II. The longer it takes for enrollment, the better I will feel. D.Right

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next